Omeros' Narsoplimab Achieves Key Trial Goal – Data Analysis Reveals Better Survival Compared to External Control in TA-TMA Patients.

Sorriso Pharmaceuticals Reveals Favorable Phase 1b Trial Results for SOR102 in Treating Ulcerative Colitis.

In recent years, a molecular target called Nectin-4 has emerged as a rising star in the field of anti-cancer drug development.

Accord Healthcare has received approval to market IMULDOSA®, a biosimilar of ustekinumab, which is similar to Stelara®.

SpliceBio has received IND clearance from the U.S. FDA for SB-007, allowing the start of Phase 1/2 clinical trials in Stargardt Disease patients.

Elevation Oncology broadens its pipeline with the introduction of EO-1022, a HER3 ADC aimed at treating solid tumors that express HER3.

Neurocrine Biosciences has received FDA approval for CRENESSITY™ (crinecerfont), the first of its kind therapy for both children and adults suffering from classic congenital adrenal hyperplasia.

Checkpoint Therapeutics reveals that the FDA has approved UNLOXCYT™ (cosibelimab-ipdl).

In the Phase 3 PATINA trial, Pfizer's IBRANCE® combined with standard treatments improved median progression-free survival by more than 15 months in patients.

This study was a Phase 2 trial assessing two doses of its unique selective cortisol modulator, dazucorilant, in patients diagnosed with ALS.

Galderma has obtained FDA approval in the U.S. for Nemluvio® (Nemolizumab) aimed at treating patients with moderate to severe atopic dermatitis.

Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), as vital components of precision medicine, have demonstrated tremendous potential in the field of gene therapy.